Patents by Inventor Kaiqiang Yan
Kaiqiang Yan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11897848Abstract: The present disclosure relates to novel crystalline forms of ozanimod and preparation method thereof. The provided crystalline forms of ozanimod comprise crystalline form CS9, crystalline form CS10 and crystalline form CS11, and can be used for treating autoimmune diseases, particularly used for preparing drugs for treating multiple sclerosis and ulcerative colitis. The crystalline forms of the present disclosure have one or more advantages in solubility, stability, hygroscopicity and processability and provide new and better choices for the preparation of ozanimod drug product, and are very valuable for drug development.Type: GrantFiled: June 4, 2021Date of Patent: February 13, 2024Assignee: RECEPTOS LLCInventors: Minhua Chen, Yanfeng Zhang, Xiaoting Zhai, Kaiqiang Yan, Chaohui Yang, Xiaoyu Zhang
-
Publication number: 20240001496Abstract: For assembling a heat pump, an apparatus includes a loading part located in an initial section of the fully automatic intelligent production line of an integrated thermal management module. The apparatus includes a first assembling part, located downstream of the loading part, that assembles a refrigerant side components of the heat pump. The apparatus includes a first testing part, located downstream of the first assembly part, that tests the refrigerant side components. The apparatus includes a second assembling part, located downstream of the loading part, that assembles the cooling water side components of the heat pump. The apparatus includes a second testing part, located downstream of the second assembling part, that tests the cooling water side components. The apparatus includes a finished product part, located downstream of the second testing part, that outputs a finished product.Type: ApplicationFiled: February 17, 2023Publication date: January 4, 2024Inventors: Shicheng Zhang, Yunpeng Hou, Yuzhi Guo, Tong Wu, Pengfei Zhang, Chunyu Dai, Kaiqiang Yan, Binqi Rao, Yan Zhang, Keyun Wang, Ke Shi
-
Patent number: 11680050Abstract: The present disclosure is directed to novel crystalline forms of ozanimod and ozanimod hydrochloride, as well as preparation method thereof. Said crystalline forms of ozanimod and ozanimod hydrochloride can be used for treating autoimmune diseases, particularly used for preparing drugs for treating multiple sclerosis and ulcerative colitis. The crystalline forms of the present disclosure have one or more advantages in solubility, melting point, stability, dissolution, bioavailability and processability and provide new and better choices for the preparation of ozanimod drug product, and are very valuable for drug development.Type: GrantFiled: January 21, 2020Date of Patent: June 20, 2023Assignee: RECEPTOS LLCInventors: Minhua Chen, Xiaoyu Zhang, Yanfeng Zhang, Chaohui Yang, Xiaoting Zhai, Kaiqiang Yan
-
Publication number: 20210292287Abstract: The present disclosure relates to novel crystalline forms of ozanimod and preparation method thereof. The provided crystalline forms of ozanimod comprise crystalline form CS9, crystalline form CS10 and crystalline form CS11, and can be used for treating autoimmune diseases, particularly used for preparing drugs for treating multiple sclerosis and ulcerative colitis. The crystalline forms of the present disclosure have one or more advantages in solubility, stability, hygroscopicity and processability and provide new and better choices for the preparation of ozanimod drug product, and are very valuable for drug development.Type: ApplicationFiled: June 4, 2021Publication date: September 23, 2021Inventors: Minhua Chen, Yanfeng Zhang, Xiaoting Zhai, Kaiqiang Yan, Chaohui Yang, Xiaoyu Zhang
-
Patent number: 11117876Abstract: The present disclosure is related to crystalline forms of ozanimod hydrochloride, as well as preparation method thereof. The crystalline form of ozanimod hydrochloride provided by the present disclosure can be used for treating autoimmune diseases, particularly multiple sclerosis and ulcerative colitis. The crystalline form of the present disclosure has advantages in at least one aspect of solubility, melting point, stability, dissolution, bioavailability and processability and provides a new and better choice for the preparation of drug product containing ozanimod, and has significant value for drug development.Type: GrantFiled: August 23, 2018Date of Patent: September 14, 2021Assignee: RECEPTOS LLCInventors: Minhua Chen, Yanfeng Zhang, Xiaoting Zhai, Kaiqiang Yan, Chaohui Yang
-
Patent number: 11111223Abstract: The present disclosure is directed to novel crystalline forms of ozanimod and ozanimod hydrochloride, as well as preparation method thereof. Said crystalline forms of ozanimod and ozanimod hydrochloride can be used for treating autoimmune diseases, particularly used for preparing drugs for treating multiple sclerosis and ulcerative colitis. The crystalline forms of the present disclosure have one or more advantages in solubility, melting point, stability, dissolution, bioavailability and processability and provide new and better choices for the preparation of ozanimod drug product, and are very valuable for drug development.Type: GrantFiled: June 14, 2017Date of Patent: September 7, 2021Assignee: RECEPTOS LLCInventors: Minhua Chen, Yanfeng Zhang, Xiaoting Zhai, Kaiqiang Yan, Chaohui Yang, Xiaoyu Zhang
-
Patent number: 11028060Abstract: The present disclosure relates to novel crystalline forms of ozanimod and preparation method thereof. The provided crystalline forms of ozanimod comprise crystalline form CS9, crystalline form CS10 and crystalline form CS11, and can be used for treating autoimmune diseases, particularly used for preparing drugs for treating multiple sclerosis and ulcerative colitis. The crystalline forms of the present disclosure have one or more advantages in solubility, stability, hygroscopicity and processability and provide new and better choices for the preparation of ozanimod drug product, and are very valuable for drug development.Type: GrantFiled: August 18, 2017Date of Patent: June 8, 2021Assignee: RECEPTOS LLCInventors: Minhua Chen, Yanfeng Zhang, Xiaoting Zhai, Kaiqiang Yan, Chaohui Yang, Xiaoyu Zhang
-
Patent number: 10882830Abstract: The present disclosure relates to crystalline form CS3 of ozanimod hydrochloride which can be used for treating autoimmune diseases, particularly used for preparing drugs for treating multiple sclerosis and ulcerative colitis and preparation method thereof.Type: GrantFiled: September 14, 2017Date of Patent: January 5, 2021Assignee: RECEPTOS LLCInventors: Minhua Chen, Yanfeng Zhang, Xiaoting Zhai, Kaiqiang Yan, Chaohui Yang, Xiaoyu Zhang
-
Publication number: 20200339524Abstract: The present disclosure is related to crystalline forms of ozanimod hydrochloride, as well as preparation method thereof. The crystalline form of ozanimod hydrochloride provided by the present disclosure can be used for treating autoimmune diseases, particularly multiple sclerosis and ulcerative colitis. The crystalline form of the present disclosure has advantages in at least one aspect of solubility, melting point, stability, dissolution, bioavailability and processability and provides a new and better choice for the preparation of drug product containing ozanimod, and has significant value for drug development.Type: ApplicationFiled: August 23, 2018Publication date: October 29, 2020Inventors: Minhua Chen, Yanfeng Zhang, Xiaoting Zhai, Kaiqiang Yan, Chaohui Yang
-
Patent number: 10815221Abstract: The present disclosure relates to novel crystalline forms of an androgen receptor antagonist drug (ODM-201 represented by formula (I)), preparation method thereof and use thereof. The crystalline form B or the crystalline form C of ODM-201 provided by the present disclosure has low hygroscopicity, good stability, high solubility, excellent flowability, optimal particle size with uniform distribution, which provides a new choice for the preparation of drugs containing ODM-201 and is of great value for drug development.Type: GrantFiled: August 25, 2017Date of Patent: October 27, 2020Assignee: Crystal Pharmaceutical (Suzhou) Co., Ltd.Inventors: Minhua Chen, Yanfeng Zhang, Kaiqiang Yan, Qiyue Liu, Xiaoyu Zhang, Jiaoyang Li
-
Patent number: 10752595Abstract: The present disclosure relates to novel crystalline forms of a bromodomain protein inhibitor 2-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]-5,7-dimethoxyquinazolin-4(3H)-one and processes for preparation and use thereof, relating to pharmaceutical industry. Form CS2, Form CS8, Form CS13, Form CS20, Form CS1, Form CS7, Form CS9, Form CS11 and Form CS4 of the present disclosure can be used for preparing drugs treating cardiovascular, cholesterol or lipid-related disorders.Type: GrantFiled: December 8, 2017Date of Patent: August 25, 2020Assignee: CRYSTAL PHARMACEUTICAL (SUZHOU) CO., LTD.Inventors: Minhua Chen, Yanfeng Zhang, Xiaoting Zhai, Kaiqiang Yan, Xiaoyu Zhang
-
Publication number: 20200239450Abstract: The present disclosure relates to novel crystalline forms of an androgen receptor antagonist drug (ODM-201 represented by formula (I)), preparation method thereof and use thereof. The crystalline form B or the crystalline form C of ODM-201 provided by the present disclosure has low hygroscopicity, good stability, high solubility, excellent flowability, optimal particle size with uniform distribution, which provides a new choice for the preparation of drugs containing ODM-201 and is of great value for drug development.Type: ApplicationFiled: August 25, 2017Publication date: July 30, 2020Applicant: CRYSTAL PHARMACEUTICAL (SUZHOU) CO., LTD.Inventors: Minhua CHEN, Yanfeng ZHANG, Kaiqiang YAN, Qiyue LIU, Xiaoyu ZHANG
-
Publication number: 20200216404Abstract: The present disclosure relates to novel crystalline forms of ozanimod and preparation method thereof. The provided crystalline forms of ozanimod comprise crystalline form CS9, crystalline form CS10 and crystalline form CS11, and can be used for treating autoimmune diseases, particularly used for preparing drugs for treating multiple sclerosis and ulcerative colitis. The crystalline forms of the present disclosure have one or more advantages in solubility, stability, hygroscopicity and processability and provide new and better choices for the preparation of ozanimod drug product, and are very valuable for drug development.Type: ApplicationFiled: August 18, 2017Publication date: July 9, 2020Applicant: CRYSTAL PHARMACEUTICAL (SUZHOU) CO., LTD.Inventors: Minhua CHEN, Yanfeng ZHANG, Xiaoting ZHAI, Kaiqiang YAN, Chaohui YANG, Xiaoyu ZHANG
-
Publication number: 20200157065Abstract: The present disclosure is directed to novel crystalline forms of ozanimod and ozanimod hydrochloride, as well as preparation method thereof. Said crystalline forms of ozanimod and ozanimod hydrochloride can be used for treating autoimmune diseases, particularly used for preparing drugs for treating multiple sclerosis and ulcerative colitis. The crystalline forms of the present disclosure have one or more advantages in solubility, melting point, stability, dissolution, bioavailability and processability and provide new and better choices for the preparation of ozanimod drug product, and are very valuable for drug development.Type: ApplicationFiled: January 21, 2020Publication date: May 21, 2020Inventors: Minhua Chen, Xiaoyu Zhang, Yanfeng Zhang, Chaohui Yang, Xiaoting Zhai, Kaiqiang Yan
-
Publication number: 20190337908Abstract: The present disclosure is directed to novel crystalline forms of ozanimod and ozanimod hydrochloride, as well as preparation method thereof. Said crystalline forms of ozanimod and ozanimod hydrochloride can be used for treating autoimmune diseases, particularly used for preparing drugs for treating multiple sclerosis and ulcerative colitis. The crystalline forms of the present disclosure have one or more advantages in solubility, melting point, stability, dissolution, bioavailability and processability and provide new and better choices for the preparation of ozanimod drug product, and are very valuable for drug development.Type: ApplicationFiled: June 14, 2017Publication date: November 7, 2019Applicant: CRYSTAL PHARMACEUTICAL (SUZHOU) CO., LTD.Inventors: Minhua CHEN, Yanfeng ZHANG, Xiaoting ZHAI, Kaiqiang YAN, Chaohui YANG, Xiaoyu ZHANG
-
Publication number: 20190330161Abstract: The present disclosure relates to novel crystalline forms of a bromodomain protein inhibitor 2-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]-5,7-dimethoxyquinazolin-4(3H)-one and processes for preparation and use thereof, relating to pharmaceutical industry. Form CS2, Form CS8, Form CS13, Form CS20, Form CS1, Form CS7, Form CS9, Form CS11 and Form CS4 of the present disclosure can be used for preparing drugs treating cardiovascular, cholesterol or lipid-related disorders.Type: ApplicationFiled: December 8, 2017Publication date: October 31, 2019Inventors: Minhua Chen, Yanfeng Zhang, Xiaoting Zhai, Kaiqiang Yan, Xiaoyu Zhang
-
Publication number: 20190248755Abstract: The present disclosure relates to crystalline form CS3 of ozanimod hydrochloride which can be used for treating autoimmune diseases, particularly used for preparing drugs for treating multiple sclerosis and ulcerative colitis and preparation method thereof.Type: ApplicationFiled: September 14, 2017Publication date: August 15, 2019Applicant: Crystal Pharmaceutical (Suzhou) Co., Ltd.Inventors: Minhua CHEN, Yanfeng ZHANG, Xiaoting ZHAI, Kaiqiang YAN, Chaohui YANG, Xiaoyu ZHANG